Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The rate of nosocomial SARS-CoV2 infections found in the different studies since the beginning of the pandemic is very variable (<1% in hospitals in the USA to about 20% in a British hospital). Mortality related to these nosocomial SARS-CoV2 infections is higher than in the general population. The risk factors identified for this nosocomial acquisition are multiple. We were confronted with nosocomial acquisitions and cluster situations in the services, without exhaustive data to measure these phenomena, and we lacked data to consider areas for improvement.
The objectives of this study are to determine the proportion of nosocomial SARS COV 2 infections in the total number of patients hospitalized with a Covid-19 infection at the CHR Metz-Thionville in 2021, and to describe the characteristics of this population.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| SARS-CoV 2 infected patients hospitalized at CHR Metz-Thionville in 2021 during the first period | SARS-CoV 2 infected patients hospitalized at CHR Metz-Thionville in April 2021 |
| |
| SARS-CoV 2 infected patients hospitalized at CHR Metz-Thionville in 2021 during the second period | SARS-CoV 2 infected patients hospitalized at CHR Metz-Thionville from June to September 2021 |
| |
| SARS-CoV 2 infected patients hospitalized at CHR Metz-Thionville in 2021 during the third period | SARS-CoV 2 infected patients hospitalized at CHR Metz-Thionville in December 2021 |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Nosocomial SARS-COV 2 Infection proportion | Other | Proportion of Nosocomial SARS-COV 2 Infections in Patients Hospitalized at the Metz-Thionville Regional Hospital in 2021 |
|
| Measure | Description | Time Frame |
|---|---|---|
| Proportion of hospital-acquired infections in patients hospitalised with a covid-19 infection | Several elements are taken into account: a) the time between entry into the establishment and the first positive SARS COV 2 PCR, b) the time between entry into the establishment and the appearance of the most frequent symptoms (fever, cough), if present in the patient, in the seven days preceding the first positive SARS COV 2 PCR, c) the existence of an epidemiological link with other infected patients, via contact in a double room with another case, and/or via hospitalisation in a department concerned by a cluster situation according to the Santé Publique France definition of May 2020 (identified on the basis of monitoring and surveillance data from the hygiene department). | up to 8 months after the third COVID-19 wave |
| Measure | Description | Time Frame |
|---|---|---|
| Description of the nosocomial infected population | age, sex, hospital unit care, outcomes of stay, vaccination status, associated conditions (comorbidities according to Charlson score, obesity, pregnancy), existence of screening on admission, time to acquisition of nosocomial infection, number of negative SARS-COV 2 PCRs in the institution before the first positive PCR, type of variant, presence of symptoms (cough, fever), stay in a double room in the 14 days prior to infection, cluster status in the ward, length of stay after infection. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Hospitalized patients with Covid-19 infection
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Mathieu LLORENS, MD | CHR Metz Thionville Hopital de Mercy | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| CHR Metz-Thionville/Hopital de Mercy | Metz | 57085 | France |
Not provided
| ID | Term |
|---|---|
| D000086382 | COVID-19 |
| ID | Term |
|---|---|
| D011024 | Pneumonia, Viral |
| D011014 | Pneumonia |
| D012141 | Respiratory Tract Infections |
| D007239 | Infections |
Not provided
Not provided
Not provided
Not provided
Not provided
| up to 8 months after the third COVID-19 wave |
| D014777 |
| Virus Diseases |
| D018352 | Coronavirus Infections |
| D003333 | Coronaviridae Infections |
| D030341 | Nidovirales Infections |
| D012327 | RNA Virus Infections |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |